Alembic Pharma's generic heart treatment drug gets USFDA approval

31 May 2024 , 10:05 AM

On thursday, Alembic Pharmaceuticals received USFDA approval to market a generic medication for certain types of heart failure.

The approved medication is Sacubitril and Valsartan Tablets, available in strengths of 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. This generic product is therapeutically equivalent to Novartis’s Entresto tablets.

Sacubitril and Valsartan tablets are used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure.

The medication is also approved for treating symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

According to IQVIA, the market size for Sacubitril and Valsartan tablets is estimated at USD 5.3 billion for the twelve months ending March 2024.

At the time of writing, shares of Alembic Pharma is trading at ₹938 which is a 0.52% dip than the previous close. The stock has gained a total of 71% in the last one year, and 22% since the beginning of the year.

For opening a demat account click on: https://www.indiainfoline.com/

For doing stock trading & investments, go to: https://ttweb.indiainfoline.com/trade/Login.aspx

For loans, go to: https://www.iifl.com/